218 related articles for article (PubMed ID: 23647717)
21. Switch from biphasic human insulin 30 to biphasic insulin aspart 30 in Pakistani subjects.
Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Mahmood S; Vohra EA
J Pak Med Assoc; 2013 Oct; 63(10):1290-4. PubMed ID: 24392563
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial).
Trippe BS; Shepherd MD; Coulter FC; Bhargava A; Brett J; Chu PL; Oyer DS
Curr Med Res Opin; 2012 Jul; 28(7):1203-11. PubMed ID: 22509859
[TBL] [Abstract][Full Text] [Related]
24. Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.
Chen L; Xing X; Lei M; Liu J; Shi Y; Li P; Qin G; Li C; Li Y; Wang Q; Gao T; Hu L; Wang Y; Yang W
Chin Med J (Engl); 2014; 127(2):208-12. PubMed ID: 24438605
[TBL] [Abstract][Full Text] [Related]
25. Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.
Belhadj M; Dahaoui A; Jamoussi H; Farouqi A
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S4-14. PubMed ID: 23958571
[TBL] [Abstract][Full Text] [Related]
26. Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis.
Guo L; Chang B; Chen L; Yang L; Liu Y; Feng B; He Q
Sci Rep; 2021 Feb; 11(1):4131. PubMed ID: 33602996
[TBL] [Abstract][Full Text] [Related]
27. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
28. Predictors of postprandial blood glucose response to biphasic insulin analogue therapy.
Borzì V; Benroubi M; Gumprecht J; Kawamori R; Ligthelm R; Shaban J; Shah S; Shestakova M; Wenying Y; Valensi P;
Prim Care Diabetes; 2013 Apr; 7(1):63-7. PubMed ID: 23182405
[TBL] [Abstract][Full Text] [Related]
29. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
[TBL] [Abstract][Full Text] [Related]
30. Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results.
Nobels F; D'Hooge D; Crenier L
Curr Med Res Opin; 2012 Jun; 28(6):1017-26. PubMed ID: 22612579
[TBL] [Abstract][Full Text] [Related]
31. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.
Davidson JA; Liebl A; Christiansen JS; Fulcher G; Ligthelm RJ; Brown P; Gylvin T; Kawamori R
Clin Ther; 2009 Aug; 31(8):1641-51. PubMed ID: 19808125
[TBL] [Abstract][Full Text] [Related]
32. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.
Gumprecht J; Benroubi M; Borzi V; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y; Ligthelm R; Valensi P;
Int J Clin Pract; 2009 Jun; 63(6):966-72. PubMed ID: 19504715
[TBL] [Abstract][Full Text] [Related]
33. Safety and effectiveness of insulin detemir in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
Soewondo P; Mohamed M; Jain AB; Sy RA; Khoo CM
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S10-6. PubMed ID: 23647712
[TBL] [Abstract][Full Text] [Related]
34. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
Linjawi S; Sothiratnam R; Sari R; Andersen H; Hiort LC; Rao P
Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
[TBL] [Abstract][Full Text] [Related]
35. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.
Liebl A; Prusty V; Valensi P; Kawamori R; Christiansen JS; Palmer AJ; Balschmidt P; Ligthelm R; Mohan V
Drugs; 2012 Jul; 72(11):1495-520. PubMed ID: 22818015
[TBL] [Abstract][Full Text] [Related]
36. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
37. Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A₁chieve study.
Chraibi A; Ajdi F; Belkhadir J; El Ansari N; Marouan F; Farouqi A
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S27-36. PubMed ID: 23958569
[TBL] [Abstract][Full Text] [Related]
38. Initiating therapy or switching to biphasic insulin aspart improves glycaemic control in type 2 diabetes: an Indian experience from the A1chieve study.
Kumar A; Sharma SK; Rajput R; Unnikrishnan AG
J Assoc Physicians India; 2013 Jan; 61(1 Suppl):16-20. PubMed ID: 24482982
[TBL] [Abstract][Full Text] [Related]
39. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Qureshi MS; Shaikh MZ
J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
[TBL] [Abstract][Full Text] [Related]
40. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
Niskanen L; Leiter LA; Franek E; Weng J; Damci T; Muñoz-Torres M; Donnet JP; Endahl L; Skjøth TV; Vaag A
Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
